Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHTCF.L Regulatory News (HTCF)

  • There is currently no data for HTCF

Company Update

18 Oct 2023 13:37

RNS Number : 5640Q
Highbridge Tactical Credit Fund Ltd
18 October 2023
 

18 October 2023

 

 

HIGHBRIDGE TACTICAL CREDIT FUND LIMITED

("HTCF" or the "Company")

 

 

 

Company Update

Compulsory redemption

The Company's board (the Board) has resolved that pursuant to Article 138(2) of the Company's articles of incorporation, and subject to the provisions of The Companies (Guernsey ) Law, 2008 (the Company Law) , the Company will compulsorily redeem the majority of the Ordinary Shares in the Company on the 1 November 2023, leaving two shareholders, holding 1 share each, being the Chairman, Vic Holmes, and director, Steve Le Page, as the Company is required to have at least one member under the Company Law and in order that they may facilitate the placing of the Company into a voluntary liquidation immediately following the redemption.

 

The Board has made the decision to compulsorily redeem these Ordinary Shares to ensure that the current shareholders are treated no less favourably than redemption creditors (being former shareholders) by a liquidator. Under the Company Law, a liquidator is obliged to discharge the claims of creditors ahead of any monies due to shareholders.

 

Compulsory Redemption Date

1 November 2023 

Compulsory Redemption Record Date

31 October 2023

Aggregate amount to be distributed to shareholders

Initially nil with the potential for future distributions net ongoing expenses

Relevant Percentage of Ordinary Shares to be Redeemed

100% of shares less one share held by each director

Compulsory Redemption Price

Based on the NAV realised by the Liquidator from the underlying assets

New ISIN

n/a due to delisting of remaining shares on or around 1 November 2023

 

Shareholders should note that any amount they may ultimately receive in respect of this redemption will vary with the value of the underlying assets and the costs of the liquidation - as is the case for existing creditors of the Company arising from previous redemption events (see the most recent financial report of the Company for details). The Board cannot estimate the value of any of the elements in the underlying AllBlue portfolio due to the complexity of the structure. The apportionment policy for the proceeds of any fines successfully imposed by the FCA is also not known as these fines relate to several years of activity by BlueCrest.

 

The Company's shares will also be suspended from trading on the London Stock Exchange on 1 November 2023. Further, it is intended that immediately following the compulsory redemption, the Company's two shareholders will hold a short notice shareholder meeting to resolve to delist the Company's shares from the London Stock Exchange and appoint a liquidator. The Company also, as a cost saving measure, does not intend to publish its financial statements for the year ended 30 June 2023.

 

AllBlue

The Company's only remaining asset except for cash is the residual holding in AllBlue Limited.

 

Your Board understands the assets of AllBlue currently consist of:

 

1. An interest in the principal value of junior secured notes issued by Fernando JSN plc, with a sale unlikely to take place in the near future.

2. Settlement agreements which were reached in June 2023 in respect of legal claims (the "Claims") that were filed in New York and London in 2018 and 2019 respectively. Once the settlement amounts are received there will be no further recoveries associated with the Claims.

3. Residual investment portfolio positions which the Liquidators of AllBlue will continue to attempt realise for maximum value, but the potential for future significant recoveries is thought to be unlikely.

 

In addition, the FCA (in the form of a FCA Decision Notice) sought to impose a financial penalty of £40,806,700 on BlueCrest Capital Management (UK) LLP (BCMUK) as well as a redress program for non-US investors. According to a FCA Press Release, the FCA considers that between October 2011 and December 2015, BCMUK failed to manage fairly a conflict of interest relating to the allocation of time spent by portfolio managers on an internal fund. BCMUK elected to challenge the FCA Decision Notice and the redress requirement before the Upper Tribunal in the UK. The Upper Tribunal issued a decision on 21st June 2023 that the FCA's approach did not satisfy the necessary legal preconditions for imposing a redress scheme. Whilst the FCA Decision Notice did not disclose the amount of redress being considered for non-US investors an amount of USD 700 million is referenced in the Upper Tribunal decision. Both the FCA and BCMUK were granted permission to appeal the Upper Tribunal decision to an appellate court. Accordingly, the timeline and final outcome of the Upper Tribunal process remains uncertain.

 

A liquidator is obliged to discharge the claims of creditors ahead of any monies due to shareholders, and any future distributions from the Liquidators of AllBlue will be distributed accordingly.

 

 

 

For further information please contact:

Sanne Fund Services (Guernsey) Limited

Company Secretary

 

Tel: +44 (0) 20 3530 3111

 

LEI: 213800397SYHLYFH5961

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDFFIFEAEDSEDS
Date   Source Headline
1st Nov 20232:02 pmRNSCompany Update
27th Oct 20235:30 pmRNSHighbridge Tactical Credit Fund
18th Oct 20231:37 pmRNSCompany Update
3rd Oct 20239:36 amRNSDirector Declaration
28th Apr 20232:33 pmRNSTotal Voting Rights
17th Apr 20237:00 amRNSShares in issue
30th Mar 20235:02 pmRNSHalf-year Report
29th Mar 20232:11 pmRNSReturn of Capital
29th Mar 20232:08 pmRNSCash Distribution
17th Mar 20234:35 pmRNSPrice Monitoring Extension
17th Mar 20237:00 amRNSDirector Declaration
16th Mar 20237:00 amRNSCompany Update and Return of Capital Information
15th Mar 20234:36 pmRNS2019 Redemption Portfolio
15th Mar 20234:30 pmRNSNet Asset Value(s)
7th Mar 20234:35 pmRNSPrice Monitoring Extension
13th Feb 20239:00 amRNSChange of Registered Office
2nd Dec 202211:44 amRNSResult of AGM
21st Nov 20223:05 pmRNSHolding(s) in Company
9th Nov 20227:00 amRNSNotice of AGM
8th Nov 20224:00 pmRNSNet Asset Value(s)
8th Nov 20224:00 pmRNS2019 Redemption Portfolio
7th Nov 20225:00 pmRNS2019 Redemption Portfolio
7th Nov 20224:58 pmRNSNet Asset Value(s)
2nd Nov 20227:00 amRNSDistribution
31st Oct 20223:22 pmRNSAnnual Financial Report
20th Oct 202210:47 amRNSAudit Opinion
18th Oct 202211:04 amRNSNet Asset Value(s)
18th Oct 202211:03 amRNS2019 Redemption Portfolio
25th Aug 20224:50 pmRNSNet Asset Value(s)
25th Aug 20224:41 pmRNS2019 Redemption Portfolio
1st Aug 20229:51 amRNS2019 Redemption Portfolio
1st Aug 20229:45 amRNSNet Asset Value(s)
5th Jul 202211:09 amRNS2019 Redemption Portfolio
5th Jul 202211:03 amRNSNet Asset Value(s)
1st Jun 202211:22 amRNSNet Asset Value(s)
1st Jun 202211:20 amRNS2019 Redemption Portfolio
7th Apr 20228:38 amRNSNet Asset Value(s)
7th Apr 20228:24 amRNS2019 Redemption Portfolio
25th Mar 202211:22 amRNSNet Asset Value(s)
25th Mar 202211:15 amRNS2019 Redemption Portfolio
22nd Mar 202211:00 amRNSCash Exit Payment
21st Mar 20223:02 pmRNSInterim Report and Accounts
2nd Mar 202210:23 amRNS2019 Redemption Portfolio
2nd Mar 202210:20 amRNSNet Asset Value(s)
23rd Feb 20224:40 pmRNSSecond Price Monitoring Extn
23rd Feb 20224:36 pmRNSPrice Monitoring Extension
21st Feb 202211:21 amRNSHolding(s) in Company
20th Jan 20225:22 pmRNSHolding(s) in Company
6th Jan 20225:06 pmRNS2019 Redemption Portfolio
6th Jan 20224:59 pmRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.